Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.37 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1677750 | 0.84 | KDM5A (0.46) | EPHX1HPGDKMT2AHDAC3HDAC4 | |
| SCHEMBL8843144 | 0.81 | EPHX1 (0.47) | EPHX1HPGDALOX5KMT2AHDAC3 | |
| SCHEMBL6877330 | 0.81 | KDM5A (0.47) | EPHX1HPGDKMT2AHDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL5392447 | 0.81 | HPGD (0.52) | EPHX1HPGDALOX5KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL1678497 | 0.79 | EPHX2 (0.50) | EPHX1HPGDKMT2ASIGMAR1 | |
| SCHEMBL885302 | 0.78 | HPGD (0.53) | EPHX1HPGDALOX5KMT2ASIGMAR1 | |
| SCHEMBL931218 | 0.78 | HPGD (0.53) | EPHX1HPGDALOX5KMT2ASIGMAR1 | |
| SCHEMBL716430 | 0.78 | SIGMAR1 (0.48) | EPHX1HPGDKMT2ASIGMAR1 | |
| SCHEMBL27617747 | 0.77 | EPHX2 (0.51) | EPHX1HPGDKMT2ASIGMAR1 | |
| SCHEMBL9100 | 0.77 | SIGMAR1 (0.50) | EPHX1HPGDALOX5KMT2AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923461-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1568692-B1 | (Pyridinyl)alkyl-amides or -ureas as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20100016380-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1743885-B1 | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| CN-100522150-C | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| US-7491739-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080182881-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7345064-B2 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20060229342-A1 | TNF-a production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| EP-1568692-A1 | (pyridin-4-yl)alkyl-amides as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| CN-1604774-A | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-04-06 | — | — | CN | disclosed |
| CN-1590375-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| CN-1590374-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| CN-1432000-A | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | CN | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229342-A1 | TNF-a production inhibitors | TNF, TNFRSF1A, TNFRSF9 | HDAC3 2567/4885HDAC4 1089/4885HDAC1 2320/4885 |
| US-20080182881-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | HDAC3 2206/4885HDAC4 882/4885HDAC1 1723/4885 |
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | HDAC3 584/4885HDAC4 235/4885HDAC1 415/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | HDAC3 620/4885HDAC4 239/4885HDAC1 419/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | HDAC3 2360/4885HDAC4 1205/4885HDAC1 1500/4885 |
| US-20100016380-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | HDAC3 1870/4885HDAC4 3609/4885HDAC1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.